{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:00:08Z","timestamp":1791910808320,"version":"4.3.4"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>Optimal duration of dual antiplatelet therapy (DAPT) in patients with concomitant indication to oral anticoagulation (OAC) is still debated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and results<\/jats:title><jats:p>A systematic review was performed on electronic databases to search for randomized controlled trials comparing an abbreviated or prolonged (\u22653 months) DAPT regimen in patients with OAC and they were analysed in the framework of standard and network meta-analyses. Co-primary endpoints were major or clinically relevant non-major bleedings (MCRB) and major bleeding, while the composite of major adverse cardiovascular events (MACE) was the key safety endpoint. Five studies and 7\u00a0665 patients (abbreviated DAPT n\u00a0=\u00a03\u00a0843; prolonged DAPT n\u00a0=\u00a03\u00a0822) were included. Both MCRB and major bleeding were lower with abbreviated DAPT [risk ratio (RR) 0.69 (0.52\u20130.91); P\u00a0=\u00a00.01 and 0.70 (0.52\u20130.95); P\u00a0=\u00a00.01, respectively] while MACE [RR: 0.96 (0.70\u20131.33); P\u00a0=\u00a00.6], all-cause death, cardiovascular death, stent thrombosis, or myocardial infarction did not differ. Network meta-analysis showed that peri-procedural DAPT had the highest probability to prevent MCRB and major bleeding (97.1 and 92.0% respectively) when compared with both short (4\u20136 weeks) and longer (\u22653 months) DAPT regimens. Sensitivity analyses and meta-regressions showed consistency in different clinical scenarios and suggested a larger bleeding reduction with P2Y12 inhibitors vs. aspirin after DAPT discontinuation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In patients undergoing PCI with concomitant OAC indication, an abbreviated DAPT regimen reduced MCRB and major bleeding without increasing MACE or other ischaemic events. Peri-procedural DAPT and P2Y12 inhibitor monotherapy after DAPT withdrawal appear to be the best strategies to optimize the bleeding and ischaemic risk tradeoff.<\/jats:p><jats:p>Trial registration. PROSPERO CRD284001<\/jats:p><\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvac065","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T16:09:53Z","timestamp":1669392593000},"page":"220-230","source":"Crossref","is-referenced-by-count":22,"title":["Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8721-0515","authenticated-orcid":false,"given":"Claudio","family":"Montalto","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine, University of Pavia , 27100 Pavia , Italy"},{"name":"De Gasperis Cardio Center, Interventional Cardiology Unit , Niguarda Hospital, 20162 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3097-2834","authenticated-orcid":false,"given":"Francesco","family":"Costa","sequence":"additional","affiliation":[{"name":"Interventional Cardiology Unit, A.O.U. Policlinic \u201cG.Martino\u201d, University of Messina , 98124 Messina , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2447-7685","authenticated-orcid":false,"given":"Sergio","family":"Leonardi","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Pavia , 27100 Pavia , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Micari","sequence":"additional","affiliation":[{"name":"Interventional Cardiology Unit, A.O.U. Policlinic \u201cG.Martino\u201d, University of Messina , 98124 Messina , Italy"},{"name":"Department of Biomedical and Dental Sciences and Morphological and Functional Imaging, A.O.U. Policlinic \u201cG. Martino\u2015 Messina University of Messina , 98122 Messina , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo A","family":"Oreglia","sequence":"additional","affiliation":[{"name":"De Gasperis Cardio Center, Interventional Cardiology Unit , Niguarda Hospital, 20162 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Vranckx","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Jessa Hospital, Stadsomvaart 11, 3500 Hasselt, Belgium; Faculty of Medicine and Life Sciences, University of Hasselt , 3500 Hasselt , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5156-7723","authenticated-orcid":false,"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u201cG. Rodolico-San Marco\u201d, University of Catania , 95123 Catania , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurri\u00ebn","family":"ten Berg","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St Antonius Hospital, 3435 Nieuwegein, Netherlands and MUMC , 6229 Maastricht , The Nehterlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2999-4961","authenticated-orcid":false,"given":"Renato D","family":"Lopes","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University Medical Center , 27708 Durham, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4353-7110","authenticated-orcid":false,"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[{"name":"Cardiocentro Ticino Institute, Division of Cardiology, and Universit\u00e0 della Svizzera italiana (USI) , 6900 Lugano , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,25]]},"reference":[{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacc.2019.05.016","article-title":"Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI: JACC State-of-the-Art review","volume":"74","author":"Capodanno","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"},{"key":"2023041009583960300_","first-page":"550","article-title":"Mortality after bleeding versus myocardial infarction in coronary artery disease: a systematic review and meta-analysis","volume":"17","author":"Piccolo","year":"2021","journal-title":"EuroIntervention J Eur Collab with Work Gr Interv Cardiol Eur Soc Cardiol"},{"key":"2023041009583960300_","article-title":"Bleeding avoidance strategies in percutaneous coronary intervention","author":"Capodanno","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","article-title":"Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data","volume":"374","author":"S\u00f8rensen","year":"2009","journal-title":"Lancet (London, England)"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamacardio.2019.6175","article-title":"Optimal antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention: an updated network Meta-analysis","volume":"5","author":"Lopes","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","article-title":"Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomi","volume":"40","author":"Gargiulo","year":"2019","journal-title":"Eur Heart J"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijcard.2019.12.054","article-title":"Double or triple antithrombotic therapy after coronary stenting and atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials","volume":"302","author":"And\u00f2","year":"2020","journal-title":"Int J Cardiol"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2046-4053-1-7","article-title":"Why prospective registration of systematic reviews makes sense","volume":"1","author":"Stewart","year":"2012","journal-title":"Syst Rev"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N Engl J Med"},{"key":"2023041009583960300_","article-title":"Abbreviated antiplatelet therapy in patients at high bleeding risk with or without oral anticoagulant therapy after coronary stenting: an open-label, randomized, controlled trial","volume":"0","author":"Smits","year":"2021","journal-title":"Circulation"},{"key":"2023041009583960300_","first-page":"1","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","article-title":"General methods for monitoring convergence of iterative simulations)?","volume":"7","author":"Brooks","year":"1998","journal-title":"J Comput Graph Stat"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test measures of funnel plot asymmetry","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12874-020-01169-7","article-title":"Using trial sequential analysis for estimating the sample sizes of further trials: example using smoking cessation intervention","volume":"20","author":"Claire","year":"2020","journal-title":"BMC Med Res Method"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12874-019-0829-2","article-title":"BUGSnet: an R package to facilitate the conduct and reporting of Bayesian network Meta-analyses","volume":"19","author":"B\u00e9liveau","year":"2019","journal-title":"BMC Med Res Method"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial","volume":"65","author":"Fiedler","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"E164","DOI":"10.4244\/EIJ-D-19-00920","article-title":"Short-duration triple antithrombotic therapy for atrial fibrillation patients who require coronary stenting: results of the SAFE - A study","volume":"16","author":"Hoshi","year":"2021","journal-title":"EuroIntervention"},{"key":"2023041009583960300_","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2020","journal-title":"Eur Heart J"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the Europe","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin k antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijcard.2018.01.065","article-title":"Clinical events after interruption of anticoagulation in patients with atrial fibrillation: an analysis from the ENGAGE AF-TIMI 48 trial","volume":"257","author":"Cavallari","year":"2018","journal-title":"Int J Cardiol"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1056\/NEJMoa035655","article-title":"Intraplaque hemorrhage and progression of coronary atheroma","volume":"349","author":"Kolodgie","year":"2003","journal-title":"N Engl J Med"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.jacc.2013.02.036","article-title":"Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation","volume":"61","author":"Sarafoff","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10557-018-6795-9","article-title":"Ticagrelor versus clopidogrel as part of dual or triple antithrombotic therapy: a systematic review and meta-analysis","volume":"32","author":"Andreou","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial","volume":"397","author":"Koo","year":"2021","journal-title":"Lancet"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jacc.2021.10.028","article-title":"Magnetically-controlled capsule endoscopy for assessment of antiplatelet Therapy-induced gastrointestinal injury","volume":"79","author":"Yaling","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1136\/gutjnl-2020-321585","article-title":"Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial","volume":"70","author":"Mahady","year":"2021","journal-title":"Gut"},{"key":"2023041009583960300_","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0140-6736(18)31714-8","article-title":"Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial","volume":"392","author":"Valgimigli","year":"2018","journal-title":"Lancet"},{"key":"2023041009583960300_","first-page":"1730","article-title":"Clinical outcomes of a real-world cohort following bioresorbable vascular scaffold implantation utilising an optimised implantation strategy","volume":"12","author":"Tanaka","year":"2017","journal-title":"EuroIntervention J Eur Collab with Work Gr Interv Cardiol Eur Soc Cardiol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvac065\/48480081\/pvac065.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/9\/3\/220\/49806078\/pvac065.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/9\/3\/220\/49806078\/pvac065.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T12:39:46Z","timestamp":1728477586000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/9\/3\/220\/6847213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,25]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,11,25]]},"published-print":{"date-parts":[[2023,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvac065","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4]]},"published":{"date-parts":[[2022,11,25]]}}}